Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

Ashish Saxena, MD, PhD, discusses available next-generation ALK inhibitors in non–small cell lung cancer.

Ashish Saxena, MD, PhD, discusses the importance of initial therapy selection in ALK-positive non–small cell lung cancer.

Ashish Saxena, MD, PhD, discusses the importance of biomarker testing for stage IV ALK-positive non–small cell lung cancer.

Lisa Newman, MD, MPH, FACS, FASCO, and Alan B. Astrow, MD, discuss the need for systemic therapy in women with microinvasive triple-negative breast cancer and more intensive adjuvant therapy in women with intermediate-risk hormone receptor-positive, HER2-negative breast cancer.

Manuel Hidalgo Medina, MD, PhD, discusses microsatellite instability and germline testing patients with pancreatic cancer.

Ashish Saxena, MD, PhD, discusses the treatment landscape of ALK-positive non–small cell lung cancer.

Manish A. Shah, MD, discusses ongoing efforts to improve immunotherapy in gastric and gastroesophageal junction cancer.

Luke Dow, PhD, discusses the next steps for researching the Wnt pathway in colorectal cancer.

Manuel Hidalgo Medina, MD, PhD, discusses treatment considerations in pancreatic cancer.

Allyson Ocean, MD, discusses the impact of the phase III PRODIGE 24/CCTG PA.6 trial on patients with pancreatic cancer.

Richard R. Furman, MD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.

Allyson Ocean, MD, discusses the use of circulating tumor DNA in pancreatic cancer.

Manish A. Shah, MD, discusses biomarkers in gastric and gastroesophageal junction cancer.

Manuel Hidalgo Medina, MD, PhD, discusses the emergence of neoadjuvant chemotherapy and radiation in pancreatic cancer.

Allyson Ocean, MD, discusses efforts to improve early detection rates in pancreatic cancer.

Brendon Stiles, MD, discusses considerations for surgery in lung cancer.

Lukas E. Dow, PhD, discusses ongoing research evaluating Wnt as a potential target in colorectal cancer.

Manish A. Shah, MD, discusses ongoing research evaluating immunotherapy and other novel treatments in advanced gastric and gastroesophageal junction cancer.

Luke Dow, PhD, discusses phase I trials targeting the Wnt signaling pathway in colorectal cancer.

Manish A. Shah, MD, discusses the use of trastuzumab biosimilars in gastric cancer.

Peter Martin, MD, associate professor of medicine, chief, the Lymphoma Program, Meyer Cancer Center, Weill Cornell Medicine, discusses the heterogeneity of mantle cell lymphoma (MCL).

Peter Martin, MD, discusses a phase I trial examining the ibrutinib plus palbociclib combination in ibrutinib-resistant patients with mantle cell lymphoma.

Leticia Varella, MD, discusses the progression of available treatments in hormone receptor-positive, HER2-negative metastatic breast cancer.

Tessa Cigler, MD, MPH, discusses the agents that are improving survival for women with early-stage and metastatic HER2-positive breast cancers.

Alan B. Astrow, MD, discusses the latest efforts to personalize patient care in early-stage, HR-positive, HER2-negative breast cancer.

Eleni Andreopoulou, MD, discusses the impact of the IMpassion130 trial on TNBC treatment and the use of immunotherapy in this patient population.

Peter Martin, MD, associate professor of medicine, chief, the Lymphoma Program, Meyer Cancer Center, Weill Cornell Medicine, discusses standard of care for younger patients with mantle cell lymphoma.

Eleni Andreopoulou, MD, associate professor of clinical medicine, Weill Cornell Medical College, associate attending physician, NewYork-Presbyterian Hospital, discusses shifts in the treatment paradigm of metastatic triple-negative breast cancer (TNBC) and the impact immunotherapy has had in the field.

Lisa Newman, MD, MPH, FACS, FASCO, highlights the history and ongoing research of the genotype causing predisposition to TNBC in African-American women.

Scott T. Tagawa, MD, discusses the impact of the BRCA2 mutation in patients with prostate cancer who are receiving prostate-specific membrane antigen–targeted radionuclide therapy.